Boardroom Alpha
Boardroom Alpha
NXTC · Additional Proxy Materials (DEFA14A) · Filed April 24, 2026

Nextcure Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 24, 2026
Ticker
NXTC
Accession
0001104659-26-048606
Boardroom Alpha · Filing insights

NextCure, Inc.'s board urges voting FOR both Class I director nominees, audit ratification, executive pay advisory, and Omnibus Plan amendment.

About Nextcure Inc
Market cap
$12M
1Y TSR
+39.5%
3Y TSR
−25.2%
Board grade
C-
Sector
Healthcare
CEO
Michael Richman
Last annual meeting: Jun 18, 2026 · View full Nextcure Inc profile →

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 14A
(Rule 14a-101)

 

Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934

Filed by the Registrant x

 

Filed by a party other than the Registrant ¨

 

Check the appropriate box:

 

¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨Definitive Proxy Statement
xDefinitive Additional Materials
¨Soliciting Material under §240.14a-12

 

[MISSING IMAGE: lg_nextcure-4c.jpg]

 

NextCure, Inc.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

xNo fee required.
¨Fee paid previously with preliminary materials.
¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

GRAPHIC

*Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V95381-P51739 NEXTCURE, INC. 9000 VIRGINIA MANOR ROAD SUITE 200 BELTSVILLE, MD 20705 Your Vote Counts! NEXTCURE, INC. 2026 Annual Meeting to Be Held on June 18, 2026 Vote by June 17, 2026 11:59 PM ET You invested in NEXTCURE, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Get informed before you vote View the Notice, Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually During the Meeting* June 18, 2026 11:00 AM ET Virtually at: www.virtualshareholdermeeting.com/NXTC2026

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V95382-P51739 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of two Class I Directors. Nominees: 1a. Anne Borgman, M.D. For 1b. John G. Houston, Ph.D. For 2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of NextCure, Inc. for the fiscal year ending December 31, 2026. For 3. Approval, on an advisory basis, of the compensation paid by Company to its named executive officers. For 4. Approval of an amendment and restatement of the Company’s 2019 Omnibus Incentive Plan to, among other items, increase the number of shares of common stock authorized for issuance thereunder. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Nextcure Inc (NXTC)

Reference

Frequently asked questions

When did Nextcure Inc file this DEFA14A?
Nextcure Inc (NXTC) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 24, 2026. The accession number assigned by EDGAR is 0001104659-26-048606.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
NextCure, Inc.'s board urges voting FOR both Class I director nominees, audit ratification, executive pay advisory, and Omnibus Plan amendment. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Nextcure Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Nextcure Inc has filed under CIK 1661059, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer